<DOC>
	<DOCNO>NCT01748539</DOCNO>
	<brief_summary>This study design evaluate efficacy safety KHK4827 subject moderate severe plaque psoriasis randomize , double-blind , placebo-controlled , parallel group study . Pharmacokinetics KHK4827 also assess .</brief_summary>
	<brief_title>A Phase 2 Clinical Study KHK4827</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject stable moderate severe plaque psoriasis least 6 month . Subject receive least one previous phototherapy systemic psoriasis therapy candidate receive phototherapy systemic psoriasis therapy opinion investigator . Subject involved BSA ≥ 10 % PASI ≥ 12 screen baseline . Subject diagnose erythrodermic psoriasis , pustular psoriasis , medicationinduced , medicationexacerbated psoriasis . Evidence skin condition time screen visit ( eg , eczema ) would interfere evaluation effect investigational product psoriasis . Subject active Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 high infection Subject significant concurrent medical condition laboratory abnormality , define study protocol . Subject use follow therapy within 14 day first dose : topical calcineurin inhibitor include tacrolimus , topical vitamin A , activated form D3 activate form D3 analogue preparation , weak strong topical steroid ( exclude application scalp , axilla , groin ) Subject use follow therapy within 28 day first dose : systemic psoriasis therapy ( eg , vitamin A , calcineurin inhibitor , methotrexate , steroid ) , UVA therapy ( without psoralen ) , strong strong topical steroid , tar therapy Subject use follow therapy within 3 month first dose : adalimumab , etanercept , infliximab , live vaccine Subject use ustekinumab within 6 month first dose Subject previously use antiinterleukin17 biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>